• Richard E. Chipkin, Ph.D., President and CEO, Psyadon Pharmaceuticals

Dr. Richard E. Chipkin, PhD, President and CEO Dr. Chipkin has more than 20 years experience at both biotech and big pharmaceutical companies. Most recently, he was President and CEO of Psychiatric Genomics. While there, he raised two rounds of venture capital financing, re-organized the company, and negotiated multiple academic licenses. Prior to that, he worked at Schering-Plough Corporation in the Global Business Development Group, where he was responsible for licensing and acquisition in multiple therapeutic areas. In this capacity, Dr. Chipkin negotiated several multi-million dollar research & development and development/marketing deals, including the license for INTEGRILIN®, currently a $250M/year product. Earlier in his career at Schering-Plough, he held positions in both preclinical and clinical neuropharmacology research. Among his accomplishments in the research arena were the discovery of novel analgesic and antipsychotic drugs, including the identification and human testing of ecopipam -- the world's first selective D1 antagonist. Dr. Chipkin received his undergraduate degree from the State University of New York at Albany and his PhD in Pharmacology from the Medical College of Virginia. He did post-doctoral work at the University of Colorado Medical Center.

Richard E. Chipkin, Ph.D. President and Chief Executive Officer Psyadon Pharmaceuticals

Richard E. Chipkin, PhD President and C.E.O. Dr. Chipkin has more than 20 years experience at both biotech and big pharmaceutical companies. Most recently, he was President and CEO of Psychiatric Genomics, a private, venture-backed company. While there, he raised two rounds of venture capital financing, re-organized the company, and negotiated multiple academic licenses. Prior to that, he worked at Schering-Plough Corporation in the Global Business Development Group, where he was responsible for licensing and acquisition in multiple therapeutic areas. In this capacity, Dr. Chipkin negotiated several multi-million dollar research & development and development/marketing deals, including the license for INTEGRILIN®, currently a $250M/year product. In addition, he was responsible for maintaining all business development relationships with Japanese pharmaceutical companies and concluded a deal with Chugai for a dermatology product. Earlier in his career at Schering-Plough, he held positions in both preclinical and clinical neuropharmacology research. Among his accomplishments in the research arena were the discovery of novel analgesic and antipsychotic drugs, including the identification and human testing of ecopipam -- the world's first selective D1/D5 antagonist. Dr. Chipkin received his undergraduate degree from the State University of New York at Albany and his PhD in Pharmacology from the Medical College of Virginia. He did post-doctoral work at the University of Colorado Medical Center.

Richard E. Chipkin, PhD President and C.E.O., Ruxton Pharmaceuticals, Inc.